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Purpose: Opioid-based intravenous patient-controlled analgesia (IV PCA) is pop-
ular method of postoperative pain control, but many patients suffer from IV PCA-
related postoperative nausea and vomiting (PONV). In this retrospective observa-
tional study, we have determined independent predictors of IV PCA-related PONV 
and predictive values of the Apfel’s simplified risk score in pursuance of identify-
ing high-risk patients. Materials and Methods: We analyzed 7000 patients who 
received IV PCA with background infusion after elective surgery. Patients who 
maintained IV PCA for a postoperative period of 48 hr (completion group, n=6128) 
were compared with those who have discontinued IV PCA within 48 hr of surgery 
due to intractable PONV (cessation group, n=872). Patients, anesthetics, and surgi-
cal factors known for predicting PONV were evaluated by logistic regression anal-
ysis to identify independent predictors of IV PCA related intractable PONV. Re-
sults: In a stepwise multivariate analysis, weight, background infusion dose of 
fentanyl, addition of ketolorac to PCA, duration of anesthesia, general anesthesia, 
head and neck surgery, and Apfel’s simplified risk score were revealed as indepen-
dent risk factors for intractable PONV followed by the cessation of IV PCA. In ad-
dition, Apfel’s simplified risk score, which demonstrated the highest odds ratio 
among the predictors, was strongly correlated with the cessation rate of IV PCA. 
Conclusion: Multimodal prophylactic antiemetic strategies and dose reduction of 
opioids may be considered as strategies for the prevention of PONV with the use 
of IV PCA, especially in patients with high Apfel’s simplified risk scores.
Key Words:   Apfel’s simplified risk score, patient-controlled analgesia, postopera-
tive nausea and vomiting 
INTRODUCTION
Intravenous patient-controlled analgesia (IV PCA) is a widely used postoperative 
analgesic strategy for its effectiveness and safety as acute postoperative pain re-
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audit and outcome assessment (more than 20000 cases at 
present). The sample population in this study was defined 
as elective surgical patients who received fentanyl-based IV 
PCA for postoperative pain control between September 2010 
and September 2011 at Severance Hospital. Patients were 
excluded for the following: age <18 years, age >80 years, 
American Society of Anesthesiologists physical status class 
≥III, requirement of postoperative ventilator support or in-
tensive care, and having received total intravenous anesthe-
sia (TIVA). Patients who maintained IV PCA for a postop-
erative period of 48 hr (completion group) were compared 
with those who discontinued IV PCA within 48 hr after sur-
gery due to intractable PONV (cessation group).
IV PCA and PONV management
General anesthesia was induced with propofol and opioids 
(remifentanil or fentanyl), and maintained with volatile an-
esthetics (isoflurane, sevoflurane, or desflurane) with/with-
out a continuous infusion of remifentanil (0.05-0.2 μg/kg/
min). All patients used the same model of disposable PCA 
pump (Accufuser plus® P2015M; Woo Young Medical, 
Chungbuk, Korea), which was programmed to deliver 2 
mL/hr as a background infusion and 0.5 mL per demand, 
with a 15-min lockout during a 48-hr period. The PCA regi-
men typically consisted of fentanyl (concentration 10-15 μg/
mL) plus normal saline (total volume of 100 mL). At the 
discretion of the attending anesthesiologists, 90-120 mg of 
ketorolac was added as an adjuvant to the PCA regimen ac-
cording to age, preoperative renal function, or type of sur-
gery. Additionally, a 5-hydroxytryptamine receptor 3 (5-
HT3) antagonists (ondansetron 4-8 mg or ramosetron 0.3 
mg) were either given at the end of surgery, or dexametha-
sone 4 mg was administered intravenously after induction 
of anesthesia. All IV PCA were started at a post-anesthesia 
care unit.
The PCA service team, which was comprised of anesthe-
siologists and PCA nurse specialists, monitored patients at 
1-6, 6-24, and 24-48 hr intervals after surgery to inquire 
about the occurrence of adverse events, and the need for 
rescue analgesics and/or antiemetics. Fentanyl-based IV 
PCA-related adverse events included PONV, sedation, diz-
ziness, headache, hypotension, and pruritis. In addition to 
these parameters, the incidence of PONV, severity of nau-
sea, and pain intensity scores were recorded at the afore-
mentioned time points. The intensity of nausea was graded 
on verbal rating scales using an 11-point scale (0=no nau-
sea to 10=worst possible nausea). Pain intensity scores were 
lief.1-3 However, postoperative analgesia using opioids is as-
sociated with a high incidence of postoperative nausea and 
vomiting (PONV), despite multimodal preventive approach-
es.4-7 Clinically, opioid-based IV PCA is occasionally discon-
tinued because of patients’ complaints of various opioid-in-
duced side effects, such as PONV, dizziness, urinary retention, 
and pruritis.1,8 In extreme cases, intractable PONV may even 
be perceived as a failure of IV PCA as a pain management 
technique. The cessation of IV PCA due to intractable PONV 
might also be an unreasonable clinical decision made by the 
surgical team because opioid-based IV PCA was thought to 
play a larger role in PONV than evidence suggested.9 The re-
lationship between opioid usage and PONV is complex, and 
applying various adjuvants with opioid sparing effects to 
multimodal analgesic regimens does not necessarily lead to a 
reduced incidence of PONV.9,10 Numerous studies have in-
vestigated the risk factors for predicting the development of 
PONV, including those related to the patient, the anesthesia, 
and the surgery.11-19 However, no such comprehensive data 
exist regarding to the association of risk factors and intracta-
ble PONV with the postoperative use of IV PCA with back-
ground infusion, which has mainly been based on the site of 
operation and the age, weight, and gender of the patient.3 
Moreover, possible risk factors for IV PCA-related PONV 
should be identified because the cessation of IV PCA may 
not only lead to discomfort, but also dissatisfy patients due to 
poor postoperative pain management and, as a result, in-
creasing hospital costs.20,21
We hypothesized that multiple factors affect the cessation 
of IV PCA caused by intractable PONV. To test our hypoth-
esis, we analyzed elective surgical patients who received 
fentanyl-based IV PCA for their postoperative pain control, 
using our large observational database. The aim of this 
study was to investigate perioperative predictive factors for 
intractable PONV accompanied by the cessation of IV 
PCA, as well as to evaluate the predictive value of the Ap-




The Institutional Review Board of Severance Hospital (ref. 
4-2011-0475) approved this study and written informed con-
sent was waived. Since 2009, the PCA service team has 
prospectively collected comprehensive clinical data for all 
postoperative PCA management for the purpose of clinical 
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Additionally, a receiver operating characteristics (ROC) 
curve was drawn. The area under the ROC-curve (AUC) 
was used to estimate the discriminating power of the Apfel 
risk score for prediction of IV PCA related PONV and the 
cut-off point for a predictive risk of IV PCA related PONV 
was calculated. Pearson correlation analysis was used to test 
the associations between weight and background infusion 
dose of fentanyl in PCA. Statistical analysis was performed 
with SAS (version 9.2; SAS Institute, Inc., Cary, NC, USA). 
Values of p<0.05 were considered as statistically significant.
RESULTS
 
A total of 9221 patients were assessed for study eligibility, of 
which 7073 initially met the study criteria. IV PCA was 
ceased within 48 hr after surgery due to fentanyl-based IV 
PCA-related adverse events for 945 patients. After the exclu-
sion of patients with other reasons for cessation of IV PCA, 
including headache and/or dizziness, hypotension, sedation, 
urinary retention and pruritis, 872 patients were included in 
the cessation group due to IV PCA-related intractable PONV. 
In the cessation group, IV PCA was ceased in 7%, 65%, and 
28% of patients 1-6, 6-24, and 24-48 hr after surgery, respec-
tively. The final study population included 7000 patients in 
measured on a visual analog scale (0 mm=no pain to 100 
mm=worst pain imaginable). IV PCA related PONV man-
agement in a general ward was conducted in regular se-
quence by institutional guidelines. 1) Patients are given IV 
rescue antiemetic (ondansetron 4 mg) if moderate to severe 
nausea (verbal rating score ≥4) lasting ≥15 min and/or emet-
ic symptoms (vomiting, retching) and/or upon the request 
of the patient; 2) If PONV is persistent 1 hr after rescue an-
tiemetic treatment, IV PCA is temporarily stopped for ap-
proximately 2 hr to identify the cause of PONV; 3) If PONV 
is persistent or relieved PONV develop by resumed IV PCA, 
additional IV antiemetic (ondansetron 4 mg or ramosetron 
0.3 mg) is given to patients; 4) The IV PCA was completely 
discontinued when intractable PONV persisted despite addi-
tional IV rescue antiemetic. Thus, IV PCA-related intracta-
ble PONV was defined as persistent nausea or emetic symp-
toms not relieved by appropriate antiemetic therapy when 
IV PCA was maintained. All prophylactic and rescue anti-
emetics that were administrated during the perioperative 
period were recorded. 
The PCA service team kept tract of the reason for cessa-
tion, time of cessation, adverse side effects, and residual vol-
ume of IV PCA if it was discontinued within 48 hr of sur-
gery. Additional patient data includes age, gender, height, 
weight, medical history, duration of anesthesia, type of an-
esthesia, type of surgery, smoking history, and previous his-
tory of motion sickness or PONV. 
 
Statistical analysis 
Continuous variables are shown as mean±standard devia-
tion, and categorical variables are shown as number (per-
centage). The variables used for analysis included demo-
graphic data (age, gender, weight) and known risk factors 
associated with PONV (background infusion dose of fentan-
yl in PCA, addition of ketorolac in PCA, type of anesthesia, 
type of surgery, duration of anesthesia, diabetes mellitus, ad-
juvant chemotherapy, Apfel’s simplified risk score). Patient 
and anesthetic characteristics were analyzed by independent 
t-test, χ2 test, or Fisher’s exact test, where appropriate. Lo-
gistic regression was used to compute crude odds ratios 
(ORs) with 95% confidence intervals (CIs) for variables as-
sociated with the cessation of IV PCA due to IV PCA-relat-
ed intractable PONV. Variables that had a p-value <0.05 
were included in the multivariate logistic regression analysis 
estimating adjusted ORs with 95% CIs. The trend of the 
cessation rate of IV PCA according to Apfel’s simplified risk 
score was analyzed using the Cochran-Armitage trend test. 
6128 patients in the  
completion group
872 patients in the cessation group
  1-6 hr period (n=65, 7%)
  2-24 hr period (n=563, 65%)
  24-48 hr period (n=224, 28%)
2148 excluded:
  <18 or 80> yr (n=1272)
  ASA physical status class ≥III (n=342)
  Requiring intensive unit care (n=483)
  TIVA (n=48)
  Incomplete data (n=3)
9221 patients in database
7073 patients met criteria
Fig. 1. Study profile. TIVA, total intravenous anesthesia; PONV, postoperative 
nausea and vomiting; IV PCA, intravenous patient-controlled analgesia; 
ASA, American Society of Anesthesiologists.
945 patients ceased IV PCA
  Intractable PONV (n=872)
  Headache and/or dizziness (n=15)
  Hypotension (n=36)
  Sedation (n=8)
  Urinary retention (n=7)
  Pruritis (n=7)
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p=0.669). In the Pearson correlation analysis, there was a 
statistically significant negative correlation between the 
background infusion dose of fentanyl in PCA and weight 
(r=-0.361, p<0.001).
In the univariate analysis, we found that female gender, 
decreased weight, increased background infusion dose of 
fentanyl in PCA, non-addition of ketorolac in PCA, decreased 
duration of anesthesia, general anesthesia, head and neck 
surgery, and the risk factors of Apfel’s simplified risk score 
were significantly associated with an increased incidence of 
IV PCA-related intractable PONV (Table 1). In the multi-
variate analysis of these variables, weight, background in-
fusion dose of fentanyl, addition of ketorolac in PCA, dura-
tion of anesthesia, general anesthesia, head and neck surgery, 
and a high Apfel simplified risk score remained indepen-
dent risk factors for IV PCA-related intractable PONV (Ta-
ble 2). Additionally, the cessation rate of IV PCA due to in-
tractable PONV was proportionally increased according to 
Apfel’s simplified risk score with statistical significance 
this observational study (6128 patients in the completion 
group and 872 patients in the cessation group) (Fig. 1). 
Data pertaining to patient characteristics, anesthesia, and 
surgery are described in Table 1. There were no significant 
differences between the completion group and the cessation 
group in age, presence of diabetes mellitus and neoadjuvant 
chemotherapy, concentration of fentanyl in PCA, and the 
number of incidence for intraoperative remifentanil infu-
sion. All patients received prophylactic antiemetic therapy 
(5-HT3 antagonists) at the end of surgery. The percentage of 
patients receiving combination prophylactic antiemetic 
therapy (5-HT3 antagonist plus dexamethasone) was also 
similar between the two groups. There was a significant dif-
ference between the three volatile anesthetics used regarding 
to the overall cessation rate (9%, 15%, and 12% after isoflu-
rane, desflurane, and sevoflurane, respectively; p<0.001), al-
though the cessation rate during the initial 1-6-hr postopera-
tive period did not differ among them (0.7%, 1.2%, and 1.1% 
after isoflurane, desflurane, and sevoflurane, respectively; 
Table 1. Patient Characteristics, Anesthetic and Surgical Data
Completion group (n=6128) Cessation group (n=872) p value
Age, yrs  51.2±15.5 51.3±15.5   0.821
Female 3330 (54.3) 622 (71.3) <0.001
Non smoker 5085 (82.9) 812 (93.1) <0.001
PONV history or motion sickness   444 (7.2) 123 (14.1) <0.001
Weight, kg  63.4±11.4 60.3±10.6 <0.001
Diabetes mellitus   643 (10.4)   90 (10.3)   0.912
Adjuvant chemotherapy   153 (2.4)   18 (2.0)   0.481
Concentration of fentanyl in PCA, μg/mL  11.0±2.3 10.9±2.4   0.092
Background dose of fentanyl in PCA, μg/kg/hr  0.34±0.1 0.36±0.1   0.001
Adjuvant ketorolac in PCA 1244 (20.3) 146 (16.7)   0.030
Duration of anesthesia, min   197±103  169±83 <0.001
Patients used intraoperative remifentanil 5228 (85.3) 757 (86.8)   0.072
Type of anesthesia   0.036
    General anesthesia 5411 (88.2) 790 (90.5)
    Regional anesthesia   717 (11.7)   82 (9.4)
Surgical procedures <0.001
    Orthopedic surgery 1271 (21.4) 196 (22.2)
    Head and neck surgery     95 (2.3)   29 (3.4)
    Laparoscopic and robotic abdominal surgery 1891 (31.1) 304 (35.1)
    Open abdomen surgery 1151 (19.4) 120 (14.3)
    Thoracic surgery   520 (8.1)   92 (11.3)
    Gynecologic surgery 1113 (18.1) 117 (13.7)
    Genitourologic surgery     87 (1.4)     9 (1.0)
Prophylactic antiemetics   0.434
    Ondansetron 3431 (55.9) 479 (54.9)
    Ramosetron 2697 (44.0) 393 (45.0)
    Dexamethasone (combination therapy)   202 (3.2)   28 (3.2)
PCA, patient controlled analgesia; PONV, postoperative nausea and vomiting.
Values are number of patients (%) or means±standard deviation.
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the study period (1-6 hr: 5% vs. 38%; 6-24 hr: 4% vs. 34%; 
24-48 hr: 1% vs. 19%; p<0.001). There were no differences 
among pain scores or the need for rescue analgesics be-
tween the two groups in each of the assessment intervals, 
except for the need for rescue analgesics in the 6-24 hr peri-
od, which was higher in the cessation group than the com-
pletion group (36% vs. 30%, p=0.008).
DISCUSSION
This is the first study to analyze which patients, anesthetics, 
and surgical variables affect intractable PONV in the opi-
oid-based IV PCA environment, resulting in the cessation 
based on the Cochran-Armitage trend test (p<0.001) (Fig. 
2). The area under the ROC curve for the Apfel risk score 
was 0.671 (95% CI 0.661-0.686) and the optimal cut-off 
point was ≥3 risk factors (corresponding sensitivity=71%, 
specificity=58%) (Fig. 3).
During the entire PONV assessment period, the percent-
age of patients experiencing PONV and receiving rescue 
antiemetics was significantly higher in the cessation group 
than in the completion group (p<0.001), except for the per-
centage of patients receiving rescue antiemetics in the 24-
48 hr postoperative period (p=0.377) (Fig. 4). The propor-
tion of patients who experienced moderate-to-severe nausea 
(verbal rating score ≥4) was also significantly higher in the 
cessation group than in the completion group throughout 
Table 2. Factors Associated with Cessation of IV PCA Due to PONV: Results of the Logistic Regression Analysis
Predictors Crude ORs (95% CI) Adjusted ORs (95% CI) p value
Age per decade 1.01 (0.99-1.01)
Gender
    Male Reference Reference
    Female 2.09 (1.79-2.44) 0.94 (0.52-1.61)   0.806
Weight per 10 kg 0.62 (0.59-0.66) 0.78 (0.73-0.82)   0.028
Diabetes mellitus
    No Reference
    Yes 0.98 (0.77-1.23)
Adjuvant chemotherapy
    No Reference
    Yes 0.82 (0.50-1.34)
Background dose of fentanyl in PCA 2.76 (1.48-5.15) 3.19 (1.47-6.61)   0.002
Adjuvant ketorolac in PCA
    No Reference Reference
    Yes 0.79 (0.65-0.95) 0.78 (0.63-0.96)   0.020
Duration of anesthesia per hr 0.83 (0.79-0.88) 0.96 (0.94-0.98) <0.001
Type of anesthesia
    Regional Anesthesia Reference Reference
    General anesthesia 1.27 (1.00-1.62) 1.51 (1.16-2.01)   0.001
Surgical procedures
    Genitourologic surgery Reference Reference
    Orthopedic surgery 1.49 (0.73-3.01) 1.23 (0.60-2.53)   0.560
    Head and neck surgery 2.95 (1.32-6.58) 3.04 (1.33-6.93)   0.008
    Laparoscopic and robotic abdominal surgery 1.55 (0.77-3.12) 1.48 (0.72-3.01)   0.280
    Open abdomen surgery 1.00 (0.49-2.05) 0.95 (0.46-1.97)   0.900
    Thoracic surgery 1.80 (0.87-3.70) 1.33 (0.63-2.77)   0.447
    Gynecologic surgery 1.01 (0.49-2.07) 0.54 (0.26-1.12)   0.098
Apfel’s simplified risk score 
    1 risk factor Reference Reference
    2 risk factors 1.82 (1.33-2.48) 1.91 (1.29-2.77) <0.001
    3 risk factors 3.07 (2.30-4.09) 3.66 (1.99-7.11) <0.001
    4 risk factors 5.36 (3.80-7.57)   6.34 (3.10-12.12) <0.001
OR, odds ratio; CI, confidence interval; PCA, patient-controlled analgesia; PONV, postoperative nausea and vomiting.
Significant variables (p<0.05) in univariate analysis were selected for multivariate analysis. 
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dict the risk of PONV with more favorable discrimination 
and calibration properties than other PONV scoring sys-
tems.14,17,22 In our multivariate analysis, the Apfel’s simpli-
fied risk score was the strongest predictive factor for IV 
PCA-related intractable PONV among the numerous pa-
tients, anesthetics and surgical parameters that we assessed. 
In addition, the Apfel’s simplified risk score was propor-
tionally correlated with an increase in the cessation rate of 
IV PCA due to PONV. The value of AUC for prediction of 
PONV using the Apfel’s simplified risk score (AUC=0.67) 
was similar to that of multi-center studies conducted in non-
IV PCA environments (AUC=0.63 to 0.72).15,17 All of the 
patients in the present study had more than one risk factor 
of the Apfel’s score (use of postoperative opioid) and re-
ceived a prophylactic antiemetic therapy. These reasons may 
of IV PCA. We identified the Apfel’s simplified risk score, 
background infusion dose of fentanyl in PCA, addition of 
ketorolac in the PCA, type of surgery, anesthetic technique, 
and duration of anesthesia as significant predictors for the 
cessation of IV PCA caused by intractable PONV. In addi-
tion, the Apfel’s simplified risk score, which demonstrated 
the highest OR among the predictors, was strongly correlat-
ed with the cessation rate of IV PCA. 
The Apfel’s simplified risk score for predicting PONV 
consists of four predictors: female gender, nonsmoking, 
history of PONV or motion sickness, and the use of postop-
erative opioids. When none, one, two, three, or four of these 
risk factors were present, it was found that the incidences of 
PONV were 10%, 21%, 39%, 61%, and 79%, respective-














































1 2 3 4
Apfelʼs simplified risk score (no. of risk factors)
0.0 0.2 0.4 0.6 0.8 1.0
1-specificity
1-6 hr 1-6 hr 1-6 hr6-24 hr 6-24 hr 6-24 hr24-48 hr 24-48 hr 24-48 hr
Nausea Vomiting/retching Antiemetics
Assessment intervals
Fig. 2. The correlation between Apfel’s simplified risk score and the cessation 
rate of IV PCA due to PONV. Data showed strong linear correlation between 
them based on Cochran-Armitage trend test (p<0.001). IV PCA, intravenous 
patient controlled analgesia; PONV, postoperative nausea and vomiting.
Fig. 3. ROC-curve for the prediction of PONV for Apfel’s simplified risk score 
(AUC 0.67, 95% CI 0.66-0.68). ROC-curve, receiver operating characteristic 
curve; PONV, postoperative nausea and vomiting; AUC, area under the ROC 
curve; CI, confidence interval.
Fig. 4. The percentages of patients experiencing PONV and receiving rescue antiemetics at 1-6, 6-24, and 24-48 hr after surgery. *p<0.001 versus completion 
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to intractable PONV in our study. This result may be ex-
plained by the close correlation between weight and the 
background infusion dose of fentanyl in the PCA despite a 
similar concentration of fentanyl between the two groups. 
In a previous study, the effect of weight on IV PCA mor-
phine requirements increased gradually from 10th percen-
tile to 80th percentile of weight but decreased at the 90th 
percentile.3 Likewise, a careful determination of fentanyl 
dosage in the IV PCA should be considered especially for 
patients with low weight. On the other hand, age was not a 
significant predictor for the cessation of IV PCA due to in-
tractable PONV in our study. Although the incidence of 
PONV is the highest in young female adults, the known ef-
fects of age are not strong enough for its incorporation in 
the risk model for PONV.12,18,22
The effect of the type of surgery on the incidence of PONV 
has been debated in the literature. Some studies have sug-
gested that the type of surgery was associated with a high 
incidence of PONV, whereas others have suggested that 
differences in the incidence of PONV were mainly due to 
patient- or anesthesia-related factors.27 In our study, we cat-
egorized the type of surgery as anatomical groups of proce-
dures to exclude the bias of narrow classifications such as 
gender, anesthetic technique, or particular surgical proce-
dure.28 We found that patients who underwent head and 
neck surgery were the highest risk for the cessation of IV 
PCA in a fentanyl-based IV PCA environment. In our cate-
gorization, head and neck surgery included extensive pro-
cedures, such as facial reconstruction surgery with wired 
jaw and radical neck dissection, which required a long dura-
tion of balanced anesthesia. In addition, head and neck sur-
gery incorporated multiple factors related to the pathogene-
sis of PONV, such as activation of target receptors in the 
chemoreceptor trigger zone and vestibular system, which 
might also explain our results.29
The duration of anesthesia is also a possible risk factor 
for PONV,11,27 although this association is not yet well es-
tablished.18,22 Interestingly, our analysis showed that a pro-
longed duration of anesthesia was associated with a reduc-
tion in the frequency of IV PCA-related intractable PONV 
and the decrease in the cessation rate of IV PCA due to 
PONV. Duration of anesthesia can be affected by various 
factors, such as type of surgery and anesthesia technique. 
The duration of anesthesia still remained an independent 
predictor for IV PCA related PONV in multivariate analysis 
with adjustment of these factors. This result might be ex-
plained by the characteristics of our study population distri-
affect the PONV predictive power of the Apfel’s score in 
our study. Female gender is the strongest single predictor 
for PONV among four predictors in Apfel’s simplified risk 
score.15 We thus included female gender in the multivariate 
analysis as a separate variable despite the possibility of in-
teractions in variables of the Apfel’s model. Female gender 
was a significant independent predictor of IV PCA related 
intractable PONV in the univariate analysis, although this 
factor did not remain significant in the multivariate analy-
sis. This result was consistent with a previous study, which 
found that the Apfel’s simplified risk score model with four 
predictors was superior to a single predictor model with fe-
male gender alone for estimating individual risk for PONV.15
Next in importance to the Apfel’s simplified risk score 
for predicting IV PCA-related intractable PONV was the 
infusion dose of fentanyl. Our results were consistent with 
previous studies that demonstrated a strong dose-response 
relationship between postoperative opioid use and PONV.23,24 
In our study, ketorolac, nonsteroidal anti-inflammatory drug, 
were combined with fentanyl as an adjuvant therapy in the 
IV PCA for approximately 20% of the analyzed patients. 
Previously, the addition of ketorolac to an opioid-based IV 
PCA has been reported to reduce postoperative opioid re-
quirements and opioid related side effects.10 We similarly 
found that the addition of ketorolac was associated with a 
reduced dose of fentanyl, which led to a decrease in the ces-
sation rate of IV PCA (11% vs. 13%, p=0.014) compared 
with the use of fentanyl alone. In our study, the IV PCA de-
vice was programmed to deliver a continuous background 
infusion, which may increase the total amount of opioid de-
livered and the incidence of side effects.25 Although the con-
sumption of fentanyl could not be assessed in each of the 
time intervals because of the simplicity of our balloon type 
PCA device, postoperative pain scores were similar be-
tween the two groups during the 48-hrpostoperative period. 
However, the need for rescue analgesics in the 6-24 hr peri-
od was higher in the cessation group than the completion 
group because the cessation of IV PCA might require addi-
tional pain treatment, especially in the acute postoperative 
pain phase.
In general, the IV PCA opioid use has primarily been 
based on gender, age, body weight, cancer, and surgical 
site.3 Body weight was found to be a significant predictor 
for IV PCA demand, although body weight and BMI ap-
peared to have little influence on the incidence of PONV.3,26 
By logistic regression analysis, low body weight were sig-
nificant factors for predicting the cessation of IV PCA due 
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strong predictors might need careful attention in the selec-
tion of intraoperative anesthetic technique, dose of fentanyl 
used in IV PCA, and prophylactic antiemetic strategies. 
These results may offer practical information for the pre-
vention of IV PCA-related PONV and the improvement of 
the quality of pain control.
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